Novo Nordisk is to launch its new diabetes drug Victoza in Japan this month, having agreed a price with the country’s authorities.

The Danish drugmaker has confirmed that it has received approval of the price of Victoza (liraglutide), the first once-daily human glucagon-like peptide-1 (GLP-1) analogue, from Japan’s Central Social Insurance Medical Council, the Chuikyo. The latter is the advisory committee to the Minister of Health, Labour and Welfare and the agreement means that the drug will be commercially launched after it is officially posted on Japan’s National Health Insurance price list on June 11.

Novo noted that Victoza will be the first GLP-1 to hit the market in Japan. It was approved in January “based on a clinical development programme specifically tailored to the needs of people with type 2 diabetes in Japan”.

Victoza has been launched in the USA and Canada as well as the UK, Germany and Denmark and a number of other European countries. A New Drug Application was submitted for approval in China in August last year and a regulatory decision is pending.

Last month, Novo announced details of the cardiovascular outcomes trial for Victoza which is set to start in the autumn which will satisfy new US Food and Drug Administration guidelines for type 2 diabetes treatments. The Phase IIIb trial will include around 9,000 patients over a five-year period.